The ZEUS failure removes a key pipeline catalyst for Novo Nordisk's cardiovascular expansion, though the financial impact is limited to a non-cash impairment. The two remaining ziltivekimab trials (HERMES, ARTEMIS) still offer upside optionality with H1 2027 readouts. Traders should watch for analyst revisions on ziltivekimab peak sales estimates and any pipeline reallocation commentary on the Q3 2026 earnings call.
Price Chart
Executive Summary
Novo Nordisk announced that ziltivekimab failed to reduce MACE vs placebo (HR 0.99, p=ns) in the ZEUS phase 3 CV outcomes trial in >6,300 patients with ASCVD, CKD, and inflammation. The drug hit its IL-6/hsCRP biomarker target but showed zero efficacy on the primary endpoint. Two sister trials (HERMES, ARTEMIS) continue with readouts expected H1 2027. The miss triggers a non-cash impairment charge in Q3 2026 but does not affect 2026 adjusted operating profit guidance. This is a material pipeline setback for a key cardiovascular asset, though the financial impact is limited to an impairment charge and the company maintains its 2026 profit outlook.
Key Facts
- Ziltivekimab failed to reduce MACE vs placebo in ZEUS phase 3 trial (HR 0.99; 95% CI 0.88–1.11)
- Trial enrolled >6,300 patients with ASCVD, CKD, and inflammation (hsCRP ≥2 mg/L)
- Drug showed expected biomarker engagement (reduced free IL-6 and hsCRP) but no CV benefit
- Safety profile similar to placebo except higher serious infection rate with ziltivekimab
- Two ongoing CVOTs (HERMES in heart failure, ARTEMIS post-heart attack) continue; readout expected H1 2027
- Failure triggers a non-cash impairment charge in Q3 2026
- 2026 adjusted operating profit guidance is unchanged
- Full results to be presented at a scientific meeting in 2026
Financial Impact
Non-cash impairment charge in Q3 2026; 2026 adjusted operating profit guidance unchanged
Risk Factors
- HERMES and ARTEMIS trials may also fail given shared IL-6 mechanism
- Impairment charge magnitude unknown; could be material if development costs were substantial
- Competitors advancing alternative anti-inflammatory CV assets (e.g., colchicine, canakinumab follow-ons)
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001171843-26-005109 |
| Document: 0001171843-26-005109-index-headers.html | 0001171843-26-005109 |
| Document: 0001171843-26-005109-index.html | 0001171843-26-005109 |
| Document: 0001171843-26-005109.txt | 0001171843-26-005109 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 15, 2026 18d ago | 6-K | $42.53 $39.40 | ▼ −7.36% | ▼ −9.49% | $37.32 (−12.25%) |
Sep 9, 2026 24d ago | 6-K | $44.56 $41.71 | ▼ −6.40% | ▼ −5.74% | $37.32 (−16.25%) |
Sep 8, 2026 25d ago | Court Ruling | $45.16 $42.53 | ▼ −5.82% | ▼ −4.70% | $37.32 (−17.36%) |
Sep 3, 2026 4w ago | Court Ruling | $47.51 $43.07 | ▼ −9.35% | ▼ −8.20% | $37.32 (−21.45%) |
Aug 24, 2026 5w ago | 6-K | $46.92 $45.33 | ▼ −3.39% | ▼ −3.86% | $37.32 (−20.46%) |
Aug 18, 2026 6w ago | 6-K | $45.71 $48.66 | ▲ +6.45% | ▲ +6.65% | $37.32 (−18.35%) |
Aug 10, 2026 7w ago | 6-K | $47.73 $44.88 | ▼ −5.97% | ▼ −5.92% | $37.32 (−21.81%) |
Aug 10, 2026 7w ago | 6-K | $47.73 $44.88 | ▼ −5.97% | ▼ −5.92% | $37.32 (−21.81%) |
Aug 4, 2026 8w ago | 6-K | $44.28 $47.17 | ▲ +6.53% | ▲ +6.63% | $37.32 (−15.72%) |
Aug 4, 2026 8w ago | 6-K | $44.28 $47.17 | ▲ +6.53% | ▲ +6.63% | $37.32 (−15.72%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access